Abiopharma

Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaqs Minimum Bid Price Requirement

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies S

Natera - Natera Acquires Foresight Diagnostics

Viridian Therapeutics, Inc. - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Iridex to Present at the Sidoti Year-End Virtual Investor Conference

Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform

Natera Acquires Foresight Diagnostics

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock